[China lymphoma diagnosis and treatment guideline (2026 edition)]

Lymphoma is one of the most common malignancies in China. Lymphoma exhibited complex pathological subtypes with significant heterogeneity, the treatment strategies varied. In recent years, with a deeper understanding of the mechanisms of oncogenesis and disease progression of lymphoma, significant development has been made in diagnosis and treatment, leading to the improvement of patients' clinical outcomes. In order to update the progress in the diagnosis and treatment of lymphoma. The Medical Oncology Branch of China International Exchange and Promotive Association for Medical and Health Care, the China Anti-cancer Association Lymphoma Committee, and the Chinese Association for Clinical Oncologists organized experts to developed the "China lymphoma diagnosis and treatment guideline (2026 edition)". The updated guideline offers systematic and comprehensive revisions on methodology, epidemiological data, clinical manifestations, auxiliary examinations, new drugs, new treatment regimens, and new indications. It also incorporates treatment recommendations along with their evidence levels and grades of recommendation, covering common clinical issues in the diagnosis and management of lymphoma patients, thus providing improved guidance for standardized diagnosis and patient management.